Until the beginning of 1962 anticoagulant therapy at this hospital was controlled by the Quick one-stage prothrombin time. The Thrombotest method of Owren (1959) , however, seemed to offer certain advantages which have been well summarized by Fichera (1962) . On theoretical grounds it has the advantage of alleged sensitivity to all the bloodclotting factors affected by oral anticoagulant drugs, prothrombin (factor II), proconvertin (factor VII), Christmas factor (factor IX), and Stuart-Prower factor (factor X). The Quick test is insensitive to changes in factor IX, so that any disproportionate fall in this factor during anticoagulant therapy would not be detected. Also it is sensitive to factor V, which is unaffected by anticoagulants. From There is considerable discussion about the desirable therapeutic range for effective anticoagulant therapy. When using the Quick test results were expressed simply as a test/control ratio, and patients were considered satisfactorily anticoagulated with a prothrombin time of 2 to 2-5 times that of the control. Variation within the range 1-9 to 2-6 was tolerated without an immediate change in dose. The acceptable Thrombotest range quoted is 10 to 25 %.
Before changing to Thrombotest, 70 patients on long-term anticoagulant therapy were examined on a single day by both methods. The results of this comparison are presented in Figure 1 . It became clear that the recommended levels for the two methods of control do not represent the same level of anticoagulation. This was also the finding of Moore and Beeler (1961) .
Only 10 patients were satisfactorily controlled by both standards. Of 34 patients judged to be well controlled by the Quick test (2-0 to 2-5), 24 had Thrombotest results of less than 10%. On the other hand, of 29 patients under-anticoagulated by the Quick test, 20 fell within the prescribed Thrombotest range.
The findings of this pilot trial were confirmed when Thrombotest was adopted as the routine method. Of 134 patients, who continued on the same dose during the changeover period, and who had a final prothrombin ratio of 2-5 or less, i.e., were well controlled or under-anticoagulated by existing standards, 94 (70%) were judged to be over-anti- Table I summarizes the results of 1,597 Quick tests before the changeover and compares them with 1,370 Thrombotest results. It shows that we are less successful, using Thrombotest, in maintaining patients within our defined therapeutic range. More patients, however, now give a result within a range which is accepted without an immediate dose change (8 to 20 %) than was the case when the prothrombin time range tolerated was 1-9 to 2 6. This may indicate acceptance of greater variation in the degree of anticoagulation than was previously permitted. group.bmj.com on October 13, 2017 -Published by http://jcp.bmj.com/ Downloaded from Table I also shows that the incidence of results suggesting potentially dangerous haemorrhagic risk has increased more than ten-fold. This might suggest that Thrombotest gives more significant warning of such risk. However, during the pilot trial of the two methods referred to above, urine specimens from all 70 patients were examined for blood, using Occultest (Ames). No patients had noticed blood in the urine, nor did any specimen show macroscopic haematuria. Four patients gave positive Occultest results, of which only one was strongly positive. This patient, who was feeling unwell and developed an overt chest infection the following day, had a Thrombotest result of 8 % but a Quick ratio of 4-5. In this case at least, the Quick test gave the more dramatic warning of an unexpected and dangerous disturbance of control. Of the three patients with weakly positive tests for blood in the urine, none had a Thrombotest result of less than 8 %. Some caution is therefore necessary in assessing the relative merits of the two tests in predicting haemorrhagic risk. (Nour-Eldin, 1959; Denson, 1961; Quick and Hussey, 1961) , and in any case the practical significance of such sensitivity in the control of anticoagulant therapy is uncertain. Rapaport and Ames (1962) have produced evidence to show that bleeding secondary to an excessive depression of factor IX is unlikely to occur in patients who are well controlled using the Quick test.
DISCUSSION
The change to Thrombotest here has resulted in acceptance of a lesser degree of anticoagulation with lower dosage in many patients. This presumably means that the haemorrhagic risk of therapy has been reduced; there is as yet no evidence to show whether patients are as adequately protected against recurrent thrombotic or embolic episodes.
For the present, there seems to be no advantage in using Thrombotest for the control of anticoagulant therapy, other than the technical advantages of the method and the desirability of the introduction of a single widely adopted method for the control of these patients.
